Literature DB >> 15176070

Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and Next Generation pharmaceutical impactors and their USP methods.

Akihiko Kamiya1, Masahiro Sakagami, Michael Hindle, Peter R Byron.   

Abstract

The particle sizing performance of a Next Generation Pharmaceutical Impactor (NGI) was compared to that of an Andersen cascade impactor (ACI). A single lot of Vanceril MDIs containing beclomethasone dipropionate (BDP) was used throughout. MDIs were sampled into NGI and ACI in accordance with USP recommendations, at 30.0 and 28.3 L/min, respectively, following 1, 2, 6, and 30 actuations with or without a silicone cup or stage coating, to determine the apparent particle size distributions (PSD) of BDP. The mass balance and the statistical comparability of drug deposits were assured on a "per actuation basis" across all experiments, demonstrating "good cascade impactor practices." Interstage deposition or "wall losses" in NGI were found to be lower than those in ACI, although their determination was laborious in NGI. The PSD profiles for Vanceril from a single actuation were distinguishable between NGI and ACI, when uncoated collection surfaces were used, most specifically for drug mass <4-microm aerodynamic diameter (p < 0.05). Silicone coating of collection surfaces and an increased number of actuations were shown to result in PSD profile shifts for both NGI and ACI. Such effects were most pronounced for NGI, although coating the collection surfaces and/or increasing the number of actuations improved drug retention significantly on the upper stages of NGI, and thereby, minimized the effects of particle bounce of BDP from Vanceril MDIs. PSD profiles from a single actuation could be determined reliably in either of these impactors, provided that coated collection surfaces were employed; also, cumulative % mass undersize profiles were similar between instruments. However, small differences in PSD profiles still existed to support NGI's design claims for reduced "overlap" in its stage collection efficiency curves. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1828-1837, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176070     DOI: 10.1002/jps.20091

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Particle size analysis in pharmaceutics: principles, methods and applications.

Authors:  Boris Y Shekunov; Pratibhash Chattopadhyay; Henry H Y Tong; Albert H L Chow
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

2.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

Review 3.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

4.  Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Authors:  Terrence P Tougas; David Christopher; Jolyon P Mitchell; Helen Strickland; Bruce Wyka; Mike Van Oort; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

5.  Respirable low-density microparticles formed in situ from aerosolized brittle matrices.

Authors:  Alan B Watts; Yi-Bo Wang; Keith P Johnston; Robert O Williams
Journal:  Pharm Res       Date:  2012-11-15       Impact factor: 4.200

6.  Evaluation and modification of commercial dry powder inhalers for the aerosolization of a submicrometer excipient enhanced growth (EEG) formulation.

Authors:  Yoen-Ju Son; P Worth Longest; Geng Tian; Michael Hindle
Journal:  Eur J Pharm Sci       Date:  2013-04-19       Impact factor: 4.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.